Cystatin C Limitations in Kidney Function Assessment in Patients with Chronic Myelomonocytic Leukemia (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #PUB013; "Data on the accuracy of cystatin C–based eGFR in CMML are limited. Case Description Case Presentation: 78-year-old woman with history of: Chronic myelomonocytic leukemia; Monoclonal gammopathy of undetermined significance; Extranodal marginal zone lymphoma of the orbit; Longstanding monocytosis and chronic anemia for >10 years; Recent progression of anemia prompted further evaluation; Serum protein electrophoresis: monoclonal protein 2.3 g/dL; Bone marrow biopsy: CMML with 5–10% plasma cell involvement Renal history: Chronic kidney disease with recurrent membranous glomerulonephritis Kidney biopsy confirmed membranous nephropathy Currently receiving rituximab Renal function assessment: Creatinine: 0.5 mg/dL → eGFR >60 mL/min/1.73m2 Cystatin C: 1.44 mg/L → eGFR 42 mL/min/1.73m2 Absolute monocyte count: 1.2 ×10^3/L → Marked discordance between creatinine- and cystatin C–based eGFR Further evaluation: Measured GFR (iothalamate): 71 mL/min/1.73m2..."
Clinical • Chronic Kidney Disease • Chronic Myelomonocytic Leukemia • Extranodal Marginal Zone Lymphoma • Glomerulonephritis • Hematological Malignancies • Leukemia • Lupus Nephritis • Lymphoma • Marginal Zone Lymphoma • Monoclonal Gammopathy • Nephrology • Renal Disease • CST3 • CTSS
|
|
Soufiane Bengelloun Zahr; Huda Faisal Sidahmed Salih; John Kevin Hix
|